Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.

Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A, Pertschuk D, Nardo C, Stern S, Elashoff R, Gammon G, Morton DL; MMAIT-IV Clinical Trial Group.

Ann Surg Oncol. 2017 Dec;24(13):3991-4000. doi: 10.1245/s10434-017-6072-3. Epub 2017 Oct 10.

PMID:
29019177
2.

Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma.

Smith FO, Yue B, Marzban SS, Walls BL, Carr M, Jackson RS, Puleo CA, Padhya T, Cruse CW, Gonzalez RJ, Sarnaik AA, Schell MJ, DeConti RC, Messina JL, Sondak VK, Zager JS.

Cancer. 2015 Sep 15;121(18):3252-60. doi: 10.1002/cncr.29452. Epub 2015 Jun 2.

3.

Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.

Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, Horak CE, Inzunza HD, Yu B, Martinez AJ, Younos I, Weber JS.

Clin Cancer Res. 2015 Feb 15;21(4):712-20. doi: 10.1158/1078-0432.CCR-14-2468. Epub 2014 Dec 18.

4.

Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck.

Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, Rao NG.

Head Neck. 2015 Jun;37(6):840-5. doi: 10.1002/hed.23684. Epub 2014 Jun 27.

PMID:
24623654
5.

Recent advances in the understanding of the genetics, etiology, and treatment of Merkel cell carcinoma.

Donepudi S, DeConti RC, Samlowski WE.

Semin Oncol. 2012 Apr;39(2):163-72. doi: 10.1053/j.seminoncol.2012.01.003. Review.

PMID:
22484188
6.

Chemotherapy of squamous cell carcinoma of the skin.

DeConti RC.

Semin Oncol. 2012 Apr;39(2):145-9. doi: 10.1053/j.seminoncol.2012.01.002. Review.

PMID:
22484186
7.

Introduction: Advanced cutaneous malignancies.

Glass LF, DeConti RC, Sondak VK.

Semin Oncol. 2012 Apr;39(2):132-3. doi: 10.1053/j.seminoncol.2012.01.012. No abstract available.

PMID:
22484183
8.

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.

Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI.

Br J Cancer. 2012 Jan 3;106(1):85-91. doi: 10.1038/bjc.2011.514. Epub 2011 Nov 29.

9.
10.

Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.

DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud AI.

Br J Cancer. 2010 Nov 9;103(10):1548-53. doi: 10.1038/sj.bjc.6605931. Epub 2010 Oct 5.

11.

Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.

Bedikian AY, DeConti RC, Conry R, Agarwala S, Papadopoulos N, Kim KB, Ernstoff M.

Ann Oncol. 2011 Apr;22(4):787-93. doi: 10.1093/annonc/mdq438. Epub 2010 Sep 20.

12.

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.

Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK.

Cancer Chemother Pharmacol. 2011 Mar;67(3):657-66. doi: 10.1007/s00280-010-1326-9. Epub 2010 May 28.

13.

A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331).

Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Balzer-Haas NS, Merl SA, DeConti RC, Thompson JA, Witter MT, Flaherty LE, Sondak VK.

Am J Clin Oncol. 2010 Oct;33(5):495-9. doi: 10.1097/COC.0b013e3181b9cf04.

14.

Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.

Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA 3rd, Lush R, Neuger A, Sullivan DM, Munster PN.

Clin Cancer Res. 2009 Apr 1;15(7):2479-87. doi: 10.1158/1078-0432.CCR-08-1931. Epub 2009 Mar 24.

15.

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R.

J Clin Oncol. 2008 Dec 20;26(36):5896-903. doi: 10.1200/JCO.2007.15.6794. Epub 2008 Nov 24.

16.

Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.

Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, Lee JH, Sondak VK, Riker AI, Deconti RC, Gabrilovich D.

J Clin Oncol. 2008 Jul 1;26(19):3235-41. doi: 10.1200/JCO.2007.13.9048.

PMID:
18591558
17.

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.

Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE.

J Clin Oncol. 2007 May 20;25(15):2078-85.

PMID:
17513813
18.

Survival after surgical resection of isolated pulmonary metastases from malignant melanoma.

Andrews S, Robinson L, Cantor A, DeConti RC.

Cancer Control. 2006 Jul;13(3):218-23.

PMID:
16885918
19.

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.

Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA; Eastern Cooperative Oncology Group.

J Clin Oncol. 2005 May 20;23(15):3562-7.

PMID:
15908667
20.

Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.

Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D.

Clin Cancer Res. 2005 Apr 15;11(8):3009-16.

21.

Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group.

Langer CJ, Li Y, Jennings T, DeConti RC, Nair S, Cohen RB, Forastiere AA; Eastern Cooperative Oncology Group.

Cancer Invest. 2004;22(6):823-31.

PMID:
15641479
22.
23.

Clinical approach to neuroendocrine carcinoma of the skin (Merkel cell carcinoma).

Smith DF, Messina JL, Perrott R, Berman CG, Reintgen DS, Cruse CW, Glass FL, Fenske NA, DeConti RC, Trotti A 3rd.

Cancer Control. 2000 Jan-Feb;7(1):72-83. Review. No abstract available.

PMID:
10740663
24.

Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin.

Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA, Glass LF.

Cancer. 1998 Jul 1;83(1):148-57.

PMID:
9655305
25.
26.

Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer.

Remick SC, Chmura M, Bromberg C, Sporn J, Healey B, Hilstro J, DeConti RC, Horton J, Ruckdeschel JC, Harper GR.

Am J Clin Oncol. 1996 Apr;19(2):125-31.

PMID:
8610634
27.

Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy.

Heller R, Jaroszeski MJ, Glass LF, Messina JL, Rapaport DP, DeConti RC, Fenske NA, Gilbert RA, Mir LM, Reintgen DS.

Cancer. 1996 Mar 1;77(5):964-71.

PMID:
8608491
28.

Perspectives on Chemotherapy of Head and Neck Cancer.

DeConti RC.

Cancer Control. 1994 Jan;1(1):24-34.

PMID:
10886948
29.

A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer.

Johnson DH, Ruckdeschel JC, Keller JH, Lyman GH, Kallas GJ, Macdonald J, DeConti RC, Lee J, Ringenberg QS, Patterson WP, et al.

Cancer. 1991 Jan 1;67(1 Suppl):245-9.

PMID:
1845847
30.
31.
32.

Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study.

Rowland KM Jr, Taylor SG 4th, Spiers AS, DeConti RC, O'Donnell MR, Showel J, Stott PB, Milner LM, Marsh JC.

Cancer Treat Rep. 1986 Apr;70(4):461-4.

PMID:
3698038
33.

Survival following moderate-dose preoperative radiation therapy for carcinoma of the rectum.

Friedmann P, Garb JL, Park WC, Stark A, DeConti RC, Chabot JR, Pace OT.

Cancer. 1985 Mar 1;55(5):967-73.

PMID:
3967205
34.

A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma.

Schoenfeld DA, Rosenbaum C, Horton J, Wolter JM, Falkson G, DeConti RC.

Cancer. 1982 Dec 15;50(12):2757-62.

PMID:
7139566
36.

Response of psoriasis to N-phosphonacetyl-L-aspartate.

Earhart RH, DeConti RC, Rubin J, Ohnuma T.

Lancet. 1981 Jun 6;1(8232):1257-8. No abstract available.

PMID:
6112581
37.
38.

Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy.

Berd D, Cornog J, DeConti RC, Levitt M, Bertino JR.

Cancer. 1975 Apr;35(4):1050-4.

PMID:
1090359
39.

Improved therapeutic index of methotrexate with "leucovorin rescue".

Levitt M, Mosher MB, DeConti RC, Farber LR, Skeel RT, Marsh JC, Mitchell MS, Papac RJ, Thomas ED, Bertino JR.

Cancer Res. 1973 Jul;33(7):1729-34. No abstract available.

40.

Development of a combination chemotherapy program for adult acute leukemia: CAM and CAM-L.

Skeel RT, Marsh JC, DeConti RC, Mitchell MS, Hubbard S, Bertino JR.

Cancer. 1973 Jul;32(1):76-81. No abstract available.

PMID:
4541476
41.

Clinical and pharmacological studies with cis-diamminedichloroplatinum (II).

DeConti RC, Toftness BR, Lange RC, Creasey WA.

Cancer Res. 1973 Jun;33(6):1310-5. No abstract available.

42.

Chemotherapy of cancer of the head and neck.

Bertino JR, Mosher MB, DeConti RC.

Cancer. 1973 May;31(5):1141-9. No abstract available.

PMID:
4122299
43.

Treatment of advanced neoplastic disease with 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037).

DeConti RC, Hubbard SP, Pinch P, Bertino JR.

Cancer Chemother Rep. 1973 Apr;57(2):201-7. No abstract available.

PMID:
4742499
44.

Continuous intravenous infusions of 5-fluoro-2'-deoxyuridine in the treatment of solid tumors.

DeConti RC, Kaplan SR, Papac RJ, Calabresi P.

Cancer. 1973 Apr;31(4):894-8. No abstract available.

PMID:
4267531
45.

Paralytic brachial neuritis in Hodgkin's disease.

Pezzimenti JF, Bruckner HW, DeConti RC.

Cancer. 1973 Mar;31(3):626-9. No abstract available.

PMID:
4693591
46.

Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone.

DeConti RC, Toftness BR, Agrawal KC, Tomchick R, Mead JA, Bertino JR, Sartorelli AC, Creasey WA.

Cancer Res. 1972 Jul;32(7):1455-62. No abstract available.

47.

Comprehensive care of adult acute leukemia.

Skeel RT, DeConti RC, Marsh JC, Mitchell MS, Bertino JR.

Conn Med. 1972 Jul;36(7):378-82. No abstract available.

PMID:
4504918
48.

Bleomycin therapy in advanced hodgkin's disease and epidermoid cancers.

Mosher MB, DeConti RC, Bertino JR.

Cancer. 1972 Jul;30(1):56-60. No abstract available.

PMID:
4114341
49.

Endotoxin stimulation in patients with lymphoma: correlation with the myelosuppressive effects of alkylating agents.

DeConti RC, Kaplan SR, Calabresi P.

Blood. 1972 May;39(5):602-9. No abstract available.

50.

Combination sequential chemotherapy in advanced reticulum cell sarcoma.

Levitt M, Marsh JC, DeConti RC, Mitchell MS, Skeel RT, Farber LR, Bertino JR.

Cancer. 1972 Mar;29(3):630-6. No abstract available.

PMID:
4551303

Supplemental Content

Loading ...
Support Center